Thelansis

IDH1-Mutated Acute Myeloid Leukemia (AML) Market Outlook Thelansis’s “IDH1-Mutated Acute Myeloid Leukemia (AML) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential IDH1-Mutated Acute Myeloid Leukemia (AML) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events wil...

IDH1-Mutated Acute Myeloid Leukemia (AML) Market Outlook Thelansis’s “IDH1-Mutated Acute Myeloid Leukemia (AML) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential IDH1-Mutated Acute Myeloid Leukemia (AML) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). IDH1-Mutated Acute Myeloid Leukemia (AML) Overview Acute myeloid leukemia (AML) is the most common type of leukemia in adults yet continues to have the lowest survival rate of all leukemias. Although rates have improved remarkably in the younger age group, the prognosis in older patients continues to be very poor. Chemotherapeutic agents, such as alkylating agents and topoisomerase...

  IDH1 mutations represent a subtype of genetic alterations observed in acute myeloid leukemia (AML), constituting approximately 20% of all AML cases. They are linked to poorer survival rates and a reduced likelihood of achieving complete remission. In younger adults with AML, IDH1 mutations occur in 6–10% of cases, while elderly patients exhibit a notably higher frequency of these mutations. Conversely, in pediatric AML cases, IDH mutations are rare, occurring in fewer than 4% of patients. These mutations drive the production of the oncometabolite 2-hydroxyglutarate, facilitating leukemogenesis by impeding normal myeloid differentiation processes. IDH1 inhibitors, oral small-molecule drugs, selectively target mutant IDH proteins to counteract this. Their mechanism involves inhibiting the production of 2-HG and promoting myeloid differentiation. IDH inhibitors can be administered alone or in conjunction with other therapies. Chronic exposure to certain chemicals significantly hei...